Overview

Fruquintinib Hepatic Impairment Study

Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
An Open-label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
Phase:
Phase 1
Details
Lead Sponsor:
Hutchison Medipharma Limited